Aquestive Therapeutics, Inc.AQSTNASDAQ
LOADING
|||
Cash Flow Under Pressure
Trending lower, below historical average, strong compound growth.
Left:
||||
Operating cash flow minus capital expenditures
Latest
$-35.92M
↓ 49% below average
Average (8y)
$-24.06M
Historical baseline
Range
High:$3.76M
Low:$-60.87M
CAGR
+18.6%
Consistent expansion
| Period | Value | Change |
|---|---|---|
| 2024 | $-35.92M | -387.0% |
| 2023 | $-7.38M | +40.1% |
| 2022 | $-12.31M | +63.7% |
| 2021 | $-33.89M | +26.3% |
| 2020 | $-45.98M | +24.5% |
| 2019 | $-60.87M | -310.9% |
| 2018 | $-14.81M | -494.4% |
| 2017 | $3.76M | +141.0% |
| 2016 | $-9.15M | - |